Are peptides legal? FDA, compounding, research-use-only and WADA rules

Important note

This page summarizes publicly reported regulatory developments for educational purposes. It is not legal advice, and the rules in this area changed repeatedly during 2025-2026. Always check the current FDA pages linked below or consult a qualified attorney.

Three ways a peptide reaches people in the U.S.

FDA-approved drugs. A manufacturer proves safety and effectiveness in clinical trials and receives approval (an NDA or BLA). Examples include semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), tesamorelin (Egrifta) and bremelanotide (Vyleesi).
Compounded drugs. Pharmacies may prepare customized medications under two sections of the Food, Drug, and Cosmetic Act ¹:

503A: state-licensed pharmacies and physicians compounding for an individual patient with a prescription.
503B: registered "outsourcing facilities" that can make larger batches, must follow current good manufacturing practice (CGMP), and are inspected by FDA.

Unapproved products sold online as "research chemicals," supplements, or cosmetics. Products intended for human use as drugs that lack approval are, in FDA's view, unapproved new drugs, regardless of the label (see "research use only" below).

The 503A bulks list and Categories 1, 2 and 3

A 503A pharmacy can compound with a bulk drug substance only if it (a) has a USP or NF monograph, (b) is a component of an FDA-approved drug, or (c) appears on FDA's 503A bulks list. The ingredient must also come from an FDA-registered manufacturer with a valid certificate of analysis ².

Because the formal list is built slowly through rulemaking, FDA uses an interim policy for nominated substances ²:

Category 1: under evaluation; FDA generally does not intend to take action against compounders using them while it decides.
Category 2: FDA has identified significant safety risks; no enforcement protection.
Category 3: nominated without enough supporting information; no enforcement protection.

In January 2025 FDA announced that substances nominated on or after January 7, 2025 will no longer be sorted into these categories ²¹².

2023: 19 substances move to Category 2

On September 29, 2023, FDA placed 19 substances, most of them popular "wellness" peptides, into Category 2: AOD-9604, BPC-157, cathelicidin LL-37, CJC-1295, dihexa acetate, emideltide (DSIP), epitalon, GHK-Cu (injectable routes), ibutamoren mesylate (MK-677, a non-peptide), ipamorelin acetate, kisspeptin-10, KPV, Melanotan II, PEG-MGF, MOTs-C, selank acetate, semax, thymosin alpha-1, and thymosin beta-4 fragment (LKKTETQ, "TB-500") ³.

FDA's stated concerns for these substances commonly included risk of immunogenicity (immune reactions, partly from aggregation and peptide-related impurities), difficulty characterizing the active ingredient, and little or no human safety data. For some, FDA cited specific reports, such as melanoma and other adverse events with Melanotan II ⁴.

2024: first withdrawals and advisory meetings

September 2024: after nominators withdrew their nominations, FDA removed AOD-9604, CJC-1295, ipamorelin, thymosin alpha-1 and selank from Category 2 ⁵.
October 29, 2024: the Pharmacy Compounding Advisory Committee (PCAC) reviewed ipamorelin, ibutamoren and kisspeptin-10, among others; FDA recommended against adding them ⁵.
December 4, 2024: the PCAC reviewed CJC-1295 (including the DAC form), AOD-9604 and thymosin alpha-1 ⁶. Law-firm analyses report the 2024 meetings did not result in any of these peptides being added to the bulks list ⁹⁷.

2026: Category 2 removals, July advisory votes, and an interim access policy

February 27, 2026: HHS Secretary Robert F. Kennedy Jr. publicly said the administration would make roughly 14 peptides more accessible through lawful compounding, according to one law-firm summary ⁷.

April 15, 2026: FDA announced that 12 peptides would leave Category 2 (effective about April 22, 2026) because their nominations were withdrawn: BPC-157, cathelicidin LL-37, dihexa acetate, emideltide (DSIP), epitalon, GHK-Cu (injectable), KPV, PEG-MGF, Melanotan II, MOTs-C, semax and TB-500 ⁹⁸⁷. Removal from Category 2 did not make them legal to compound; it moved them into a regulatory gray zone pending review ⁷⁹.

June 29, 2026: FDA staff reviews recommended against adding seven peptides to the bulks list; FDA also reconstituted the PCAC the same day ¹³.

July 23-24, 2026 PCAC votes (advisory, non-binding) ¹¹¹⁰¹³:

Peptide	Proposed use reviewed	Vote
BPC-157	Ulcerative colitis	8-6 (1 abstain) - recommended
KPV	Wounds, inflammatory conditions	8-6 (1 abstain) - recommended
TB-500	Wound healing	8-6 (1 abstain) - recommended
MOTs-C	Obesity, osteoporosis	7-5 (2 abstain) - recommended
Epitalon	Insomnia	7-4 (1 abstain) - recommended
Semax	Cerebral ischemia, migraine, trigeminal neuralgia	8-5 (1 abstain) - recommended
Emideltide (DSIP)	Opioid withdrawal, insomnia, narcolepsy	6-7 (1 abstain) - not recommended

A second PCAC meeting on GHK-Cu (injectable), LL-37, dihexa, Melanotan II and PEG-MGF is expected before the end of February 2027 ⁸¹³.

What the votes do not do: they do not add anything to the bulks list. That requires a proposed rule, public comment and a final rule, which historically has taken years (a 2016 proposal was finalized in 2019) ¹²¹³.

October 2026: "Interim Access Policy." On October 14–15, 2026 (sources differ by a day), HHS and FDA sent an "Interim Access Policy for Compounding Using Certain Peptides" to the White House Office of Management and Budget for review ¹⁴¹⁵¹³. Reports describe it as enforcement discretion (FDA choosing not to act against qualifying compounders) rather than approval, and its list of peptides and conditions had not been published as of late October 2026. Even if issued, it would not cover research-use-only sellers or supplements, and state pharmacy and medical-practice laws would still apply ¹³¹⁵.

Current FDA category list (May 14, 2026): Category 1 includes GHK-Cu for non-injectable routes, vasoactive intestinal peptide, alanyl-L-glutamine and glutathione; kisspeptin-10 remains in Category 2; GHRP-2 and GHRP-6 appear in Category 3 ¹⁶. Check FDA's page for the latest version.

"Research use only" is not a legal shield

Many online sellers label vials "for research use only" or "not for human consumption." FDA looks at the objective evidence of intended use, not just the disclaimer. In 2026 warning letters FDA cited:

Gram Peptides (March 31, 2026): retatrutide and tirzepatide labeled research-use-only, but marketed with weight-loss and metabolic claims; FDA also treated the bacteriostatic water sold alongside them as a drug ¹⁷.
Wholesale Peptide (June 17, 2026): "Prostamax" and gonadorelin, with prostate and testosterone claims, despite "RESEARCH USE ONLY" labeling ¹⁸.
August 24, 2026: warning letters to online peptide vendors. One law-firm analysis names four companies (Royal Peptides, Peptide Partners, NuScience Peptides and Peak Performance Peptides) selling products including semaglutide, tirzepatide, retatrutide, SS-31, PT-141 and tesamorelin; another reports five letters. FDA pointed to health claims, sales of bacteriostatic water, and (in at least one letter) a dosing calculator and "peptide guide" as proof the products were meant for people ¹⁹¹³. These letters had not been confirmed on fda.gov in this review.

FDA also stresses that injectable products carry extra risk because they bypass the body's natural defenses against microbes and toxins ¹⁷¹⁹.

GLP-1 shortages end and the compounding crackdown

During the 2022-2024 shortages of semaglutide and tirzepatide, compounders were legally allowed to make copies. That window closed:

Tirzepatide: FDA confirmed the shortage resolved on December 19, 2024; enforcement discretion ended February 18, 2025 for 503A pharmacies and March 19, 2025 for 503B facilities ²⁰.
Semaglutide: FDA declared the shortage resolved in February 2025; discretion ended April 22, 2025 (503A) and May 22, 2025 (503B) ²¹.
September 9, 2025: FDA and HHS announced an advertising crackdown, including thousands of letters and about 100 cease-and-desist letters to drug and telehealth companies ²².
March 3, 2026: FDA issued 30 warning letters to telehealth firms over misleading compounded GLP-1 marketing, such as claims that compounded products are the "same" as brand-name drugs ²³.
September 18, 2026: FDA issued a warning letter about compounded GLP-1 products with added B12 or niacinamide ¹³.

DEA and controlled-substance status

Most peptides are not controlled substances under the federal Controlled Substances Act, so possessing them is not a DEA matter in the way steroids or opioids are. They are regulated mainly by FDA as drugs. Notable nuances (check DEA's current schedules list ²⁴):

Anabolic steroids (Schedule III) are not peptides, but they are often sold alongside peptides.
Human chorionic gonadotropin (hCG) is not federally scheduled, but some states control it as a scheduled substance; check state law.
Human growth hormone is not scheduled, but federal law (21 U.S.C. 333(e)) makes distributing it for non-approved uses a specific crime.

Not being "scheduled" does not mean a product is legal to sell for human use; unapproved drug rules still apply.

Sports and anti-doping (WADA)

For athletes subject to the World Anti-Doping Code, many peptides are banned at all times under the 2026 Prohibited List ²⁵:

S0 Non-approved substances: any substance not approved by a government health authority for human therapeutic use. BPC-157 is named as an example.
S2 Peptide hormones, growth factors, related substances and mimetics: includes GHRH analogs (CJC-1295, sermorelin, tesamorelin), growth hormone secretagogues (ipamorelin, MK-677), GHRPs (GHRP-6), GH fragments (AOD-9604), testosterone-stimulating peptides in males (hCG, LH, GnRH analogs, kisspeptin), IGF-1 and analogs, mechano growth factors, and thymosin beta-4 derivatives such as TB-500.
S4.4 Metabolic modulators: includes AMPK activators such as MOTS-c, plus insulins.

The list is not exhaustive and adds "and other substances with similar chemical structure or biological effects." Athletes should check with their anti-doping organization (in the U.S., USADA's Global DRO).

Personal importation

FDA has a narrow personal-importation enforcement policy that may allow individuals to bring in limited quantities (generally up to a 90-day supply) of an unapproved drug for a serious condition with no satisfactory U.S. treatment, under a doctor's care, when the product poses no unreasonable risk ²⁶. It is discretionary, does not apply to products for which FDA has safety concerns, and does not authorize businesses to import for resale. FDA also maintains import alerts targeting unverified GLP-1 active ingredients ²³.

Quick international notes

Rules differ by country; verify with each regulator.

United Kingdom: peptides marketed for medical use are medicines regulated by the MHRA; selling unlicensed medicines to the public is an offense, and "research" labeling does not change that ²⁷.
European Union: medicines require authorization from the EMA or national agencies; EMA warns consumers to buy only from registered online pharmacies displaying the EU common logo ²⁸.
Australia: many performance and wellness peptides (such as GH secretagogues) are prescription-only (Schedule 4) under the Poisons Standard, and importing them without a valid prescription can breach TGA and border rules; Sport Integrity Australia has repeatedly warned about black-market peptides ²⁹.
Canada: Health Canada considers products making health claims to be drugs requiring authorization, and warns against buying unauthorized drugs online ³⁰.

Peptide Regulation in the United States and Abroad (updated October 2026)